Commercial Physical & Biological Research Industry - SEC Form 4 Insider Trading Screener
Services Sector - Engineering, Accounting, Research, Management Services - Commercial Physical & Biological Research
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2018-07-18 | XON | Intrexon Corp | Sabzevari Helen | Pres, Precigen, Inc. | S - Sale+OE | $14.54 | -8,402 | 16,598 | -34% | -$122,165 | |||||
| D | 2018-07-17 | CRL | Charles River Laboratories International Inc | Molho Davide | Pres, COO | S - Sale+OE | $120.00 | -11,126 | 74,427 | -13% | -$1,335,120 | |||||
| D | 2018-07-16 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale+OE | $3.40 | -39,497 | 2,164,330 | -2% | -$134,290 | |||||
2018-07-17 | CRL | Charles River Laboratories International Inc | Girshick Birgit | Corporate EVP | S - Sale | $119.90 | -3,978 | 18,999 | -17% | -$476,962 | ||||||
| D | 2018-07-16 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $21.13 | -90,000 | 318,705 | -22% | -$1,901,700 | |||||
| AM | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-09 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -8,955 | 2,044,730 | 0% | -$30,447 | ||||||
| D | 2018-07-09 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $71.11 | -10,000 | 32,963 | -23% | -$711,100 | |||||
2018-07-09 | INCY | Incyte Corp | Iyengar Vijay K | EVP GPS, BD, Licensing | S - Sale | $71.34 | -606 | 8,103 | -7% | -$43,232 | ||||||
| M | 2018-07-06 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -6,994 | 5,716,010 | 0% | -$265,772 | |||||
2018-07-03 | XON | Intrexon Corp | Kirk Randal J | CEO, 10% | P - Purchase | $13.37 | +7,479,431 | 66,789,237 | +13% | +$99,999,992 | ||||||
| M | 2018-07-03 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.00 | -7,719 | 5,723,004 | 0% | -$293,347 | |||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.55 | -2,775 | 322,178 | -1% | -$309,540 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.34 | -5,348 | 274,451 | -2% | -$595,462 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $111.11 | -5,471 | 279,799 | -2% | -$607,865 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $110.80 | -5,005 | 285,270 | -2% | -$554,552 | ||||||
2018-07-02 | CRL | Charles River Laboratories International Inc | Foster James C | COB, CEO | S - Sale | $110.53 | -6,401 | 290,275 | -2% | -$707,472 | ||||||
| D | 2018-07-02 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $21.20 | -22,500 | 292,793 | -7% | -$477,000 | |||||
| D | 2018-07-02 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $59.10 | -2,135 | 77,048 | -3% | -$126,176 | |||||
| D | 2018-06-25 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $19.62 | -90,000 | 318,705 | -22% | -$1,765,800 | |||||
| M | 2018-06-25 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.01 | -15,358 | 5,730,723 | 0% | -$583,762 | |||||
2018-06-25 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $115.55 | -300 | 13,837 | -2% | -$34,665 | ||||||
| D | 2018-06-25 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale+OE | $114.05 | -3,230 | 14,137 | -19% | -$368,381 | |||||
| M | 2018-06-21 | NRC | National Research Corp | K/i/e/trust Under Agreement 3/9/09 | 10% | S - Sale | $38.04 | -5,441 | 5,746,081 | 0% | -$207,002 | |||||
| D | 2018-06-15 | IQV | Iqvia Holdings Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $103.20 | -92,160 | 1,331,519 | -6% | -$9,510,912 | |||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Cpp Investment Board Private Holdings, Inc. | 10% | S - Sale | $103.00 | -9,291,036 | 7,453,388 | -55% | -$956,976,708 | ||||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Dir | S - Sale | $103.00 | -6,716,253 | 16,149,276 | -29% | -$691,774,059 | ||||||
2018-06-15 | IQV | Iqvia Holdings Inc. | Connaughton John | Dir | S - Sale | $103.00 | -1,441,236 | 3,815,315 | -27% | -$148,447,308 | ||||||
2018-06-14 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $41.80 | -3,000,000 | 10,399,997 | -22% | -$125,400,000 | ||||||
2018-05-31 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -100 | 2,053,685 | 0% | -$340 | ||||||
2018-05-31 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $20.71 | -65,000 | 255,067 | -20% | -$1,346,150 | ||||||
| D | 2018-05-30 | EXEL | Exelixis, Inc. | Feldbaum Carl B | Dir | S - Sale+OE | $20.60 | -34,262 | 15,221 | -69% | -$705,797 | |||||
| D | 2018-06-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $20.80 | -22,500 | 292,793 | -7% | -$468,000 | |||||
| M | 2018-05-25 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.41 | -6,700 | 2,053,785 | 0% | -$22,841 | |||||
| D | 2018-05-23 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $33.88 | -5,066 | 26,894 | -16% | -$171,618 | |||||
| D | 2018-05-22 | EXEL | Exelixis, Inc. | Willsey Lance | Dir | S - Sale+OE | $21.40 | -50,000 | 418,273 | -11% | -$1,070,000 | |||||
| D | 2018-05-24 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $20.55 | -90,000 | 318,705 | -22% | -$1,849,500 | |||||
| DM | 2018-05-21 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.50 | -13,401 | 31,894 | -30% | -$462,295 | |||||
2018-05-21 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -915 | 2,060,485 | 0% | -$3,111 | ||||||
2018-05-22 | ELOX | Eloxx Pharmaceuticals, Inc. | Ward Robert | CEO | P - Purchase | $14.34 | +5,000 | 15,000 | +50% | +$71,700 | ||||||
| DM | 2018-05-18 | NRCI | National Research Corp | Berwick Donald M | Dir | S - Sale+OE | $34.54 | -25,309 | 0 | -100% | -$874,231 | |||||
| M | 2018-05-17 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -102,930 | 2,061,400 | -5% | -$349,962 | |||||
| DM | 2018-05-17 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.66 | -31,778 | 31,894 | -50% | -$1,101,487 | |||||
2018-05-18 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale | $21.61 | -3,663 | 160,967 | -2% | -$79,157 | ||||||
| D | 2018-05-16 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.67 | -5,952 | 41,139 | -13% | -$206,384 | |||||
| DM | 2018-05-14 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.47 | -22,985 | 41,894 | -35% | -$792,364 | |||||
2018-05-15 | PIRS | Pieris Pharmaceuticals, Inc. | Geraghty James A | Dir | P - Purchase | $5.75 | +10,000 | 20,000 | +100% | +$57,500 | ||||||
2018-05-14 | CRL | Charles River Laboratories International Inc | Massaro George | Dir | S - Sale | $107.19 | -1,218 | 13,837 | -8% | -$130,558 | ||||||
2018-05-10 | IQV | Iqvia Holdings Inc. | Evanisko Michael J | Dir | S - Sale | $100.00 | -815 | 7,358 | -10% | -$81,500 | ||||||
| DM | 2018-05-10 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $33.90 | -18,514 | 41,894 | -31% | -$627,538 | |||||
| D | 2018-05-11 | EXEL | Exelixis, Inc. | Marchesi Vincent T | Dir | S - Sale+OE | $19.03 | -15,000 | 125,913 | -11% | -$285,450 | |||||
2018-05-10 | EXAS | Exact Sciences Corp | Wyzga Michael S | Dir | S - Sale | $51.53 | -7,402 | 10,974 | -40% | -$381,447 | ||||||
| D | 2018-05-09 | EXEL | Exelixis, Inc. | Cohen Charles | Dir | S - Sale+OE | $21.42 | -15,000 | 248,180 | -6% | -$321,300 | |||||
| M | 2018-05-08 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.43 | -64,608 | 2,075,444 | -3% | -$221,341 | |||||
| D | 2018-05-09 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $33.31 | -8,654 | 51,894 | -14% | -$288,239 | |||||
| DM | 2018-05-07 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.13 | -8,594 | 51,894 | -14% | -$293,300 | |||||
2018-05-07 | MEDP | Medpace Holdings, Inc. | Medpace Limited Partnership | 10% | S - Sale | $35.49 | -3,000,000 | 13,399,997 | -18% | -$106,470,000 | ||||||
| D | 2018-05-07 | EXEL | Exelixis, Inc. | Papadopoulos Stelios | Dir | S - Sale+OE | $22.15 | -15,000 | 1,034,314 | -1% | -$332,250 | |||||
2018-05-04 | EXEL | Exelixis, Inc. | Hessekiel Jeffrey | EVP, GC | S - Sale | $22.36 | -20,000 | 320,067 | -6% | -$447,200 | ||||||
| DM | 2018-05-04 | EXEL | Exelixis, Inc. | Haley Patrick J. | SVP, Commercial | S - Sale+OE | $22.17 | -27,549 | 164,630 | -14% | -$610,847 | |||||
| D | 2018-05-03 | NRCI | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $34.49 | -18,056 | 51,894 | -26% | -$622,833 | |||||
2018-05-03 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.40 | -3,900 | 2,140,052 | 0% | -$13,260 | ||||||
| D | 2018-05-03 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres Prod Dev, Med Aff, CMO | S - Sale+OE | $23.09 | -22,500 | 292,793 | -7% | -$519,417 | |||||
2018-05-02 | INCY | Incyte Corp | Hoppenot Herve | COB , CEO | P - Purchase | $60.94 | +15,000 | 276,690 | +6% | +$914,100 | ||||||
| M | 2018-05-01 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.41 | -20,378 | 2,143,952 | -1% | -$69,489 | |||||
| D | 2018-05-01 | CRL | Charles River Laboratories International Inc | Smith David Ross | Corporate EVP, CFO | S - Sale+OE | $104.23 | -945 | 12,778 | -7% | -$98,499 | |||||
2018-04-30 | PIRS | Pieris Pharmaceuticals, Inc. | Orbimed Advisors LLC | See Remarks, 10% | S - Sale | $6.35 | -1,000,000 | 38,870 | -96% | -$6,350,000 | ||||||
| D | 2018-04-30 | INCY | Incyte Corp | Swain Paula J | EVP, HR | S - Sale+OE | $62.43 | -80,000 | 33,367 | -71% | -$4,994,400 | |||||
2018-04-30 | ELOX | Eloxx Pharmaceuticals, Inc. | Shabtai Gilad | 10% | P - Purchase | $9.75 | +75,000 | 3,351,770 | +2% | +$731,250 | ||||||
2018-04-30 | ELOX | Eloxx Pharmaceuticals, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% | P - Purchase | $9.75 | +350,000 | 520,396 | +205% | +$3,412,500 | ||||||
2018-04-30 | ELOX | Eloxx Pharmaceuticals, Inc. | Nussbaum Ran | Dir | P - Purchase | $9.75 | +350,000 | 7,708,582 | +5% | +$3,412,500 | ||||||
2018-04-30 | ELOX | Eloxx Pharmaceuticals, Inc. | Kleijwegt Martijn | Dir | P - Purchase | $9.75 | +300,000 | 2,953,673 | +11% | +$2,925,000 | ||||||
2018-04-30 | ELOX | Eloxx Pharmaceuticals, Inc. | Kariv Tomer | Dir | P - Purchase | $9.75 | +350,000 | 7,708,582 | +5% | +$3,412,500 | ||||||
| D | 2018-04-23 | NRCI | National Research Corp | Hays Michael D. | CEO | S - Sale+OE | $35.00 | -80 | 141,166 | 0% | -$2,800 | |||||
2018-04-18 | IQV | Iqvia Holdings Inc. | Evanisko Michael J | Dir | S - Sale | $100.00 | -815 | 6,101 | -12% | -$81,500 | ||||||
| D | 2018-04-16 | EXEL | Exelixis, Inc. | Wyszomierski Jack L | Dir | S - Sale+OE | $20.25 | -14,959 | 93,844 | -14% | -$302,920 | |||||
| D | 2018-04-16 | EXEL | Exelixis, Inc. | Garber Alan M | Dir | S - Sale+OE | $20.25 | -15,000 | 61,329 | -20% | -$303,750 | |||||
| M | 2018-04-16 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.41 | -39,172 | 2,046,313 | -2% | -$133,522 | |||||
| DM | 2018-04-12 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale+OE | $3.39 | -78,045 | 2,085,485 | -4% | -$264,262 | |||||
| D | 2018-04-11 | EXEL | Exelixis, Inc. | Morrissey Michael | Pres, CEO | S - Sale+OE | $20.78 | -90,000 | 318,604 | -22% | -$1,870,200 | |||||
2018-04-12 | EXAS | Exact Sciences Corp | Zanotti Katherine S | Dir | S - Sale | $45.00 | -7,232 | 105,814 | -6% | -$325,440 | ||||||
| M | 2018-04-10 | LUNA | Luna Innovations Inc | Carilion Clinic | 10% | S - Sale | $3.43 | -44,012 | 2,120,318 | -2% | -$151,014 | |||||
2018-04-10 | EXAS | Exact Sciences Corp | Doyle James Edward | Dir | S - Sale | $40.97 | -3,098 | 35,181 | -8% | -$126,925 | ||||||
2018-04-10 | EXAS | Exact Sciences Corp | Carey Thomas D. | Dir | S - Sale | $39.73 | -8,448 | 52,410 | -14% | -$335,630 | ||||||
| M | 2018-04-03 | ELOX | Eloxx Pharmaceuticals, Inc. | Shabtai Gilad | 10% | P - Purchase | $9.46 | +8,300 | 3,276,770 | 0% | +$78,545 | |||||
| D | 2018-04-02 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.75 | -3,000 | 32,600 | -8% | -$86,250 | |||||
| D | 2018-04-02 | EXAS | Exact Sciences Corp | Coward D Scott | SVP, GC | S - Sale+OE | $40.12 | -2,122 | 70,690 | -3% | -$85,124 | |||||
2018-03-29 | ELOX | Eloxx Pharmaceuticals, Inc. | Shabtai Gilad | 10% | P - Purchase | $9.64 | +4,500 | 3,268,470 | 0% | +$43,380 | ||||||
| D | 2018-03-29 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $29.50 | -100 | 32,600 | 0% | -$2,950 | |||||
| D | 2018-03-28 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.87 | -4,068 | 32,600 | -11% | -$117,441 | |||||
2018-03-26 | ELOX | Eloxx Pharmaceuticals, Inc. | Avnur Zafrira | Dir | P - Purchase | $9.49 | +2,000 | 2,263 | +760% | +$18,980 | ||||||
| DM | 2018-03-26 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $28.66 | -4,991 | 32,600 | -13% | -$143,043 | |||||
| DM | 2018-03-22 | NRCIA | National Research Corp | Nunnelly John N | Dir | S - Sale+OE | $30.15 | -356 | 32,600 | -1% | -$10,732 | |||||
2018-03-23 | ELOX | Eloxx Pharmaceuticals, Inc. | Ward Robert | CEO | P - Purchase | $8.99 | +10,000 | 10,000 | New | +$89,900 | ||||||
2018-03-23 | ELOX | Eloxx Pharmaceuticals, Inc. | Weaver Gregory L | CFO | P - Purchase | $8.56 | +4,500 | 4,500 | New | +$38,520 | ||||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Nussbaum Ran | Dir | P - Purchase | $7.76 | +12,600 | 7,615,249 | 0% | +$97,830 | |||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Kariv Tomer | Dir | P - Purchase | $7.76 | +12,600 | 7,615,249 | 0% | +$97,830 | |||||
| M | 2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% | P - Purchase | $7.76 | +12,600 | 427,063 | +3% | +$97,830 | |||||
2018-03-21 | ELOX | Eloxx Pharmaceuticals, Inc. | Avnur Zafrira | Dir | P - Purchase | $7.60 | +263 | 263 | New | +$1,999 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |